Key result
Off-label use of an 18-mm Amplatzer Patent Foramen Ovale Occluder device successfully reduced severe recurrent commissural mitral regurgitation to mild regurgitation and improved exertional dyspnea.
Why the study?
Mitral regurgitation may recur after MitraClip intervention and repeat clipping or surgery may not be feasible, posing a management dilemma.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
An Amplatzer PFO Occluder device may be used off-label to successfully manage severe recurrent commissural mitral regurgitation following MitraClip when repeat clipping or surgery is not feasible.
Mitral regurgitation (MR) is a common valvular abnormality in patients in the Western world. Treatment options include surgery and edge-to-edge repair of the mitral valve leaflets using the MitraClip device. However, MR may recur, and MitraClip can be unsuccessful, posing a challenging management dilemma. We present a case involving a 74-year-old male patient who originally presented due to severe symptomatic MR. The patient originally underwent successful intervention with a MitraClip. However, the patient reported recurrent dyspnea with little effort approximately six months after the index procedure. A repeat 3D transesophageal echocardiogram revealed severe recurrent MR at the medial commissure with an eccentric jet, similar to findings from prior studies. Due to the medial location of the defect, limited space to steer an additional clip, and high surgical risk, the patient was not a suitable candidate for surgical intervention or repeat MitraClip (Abbott Vascular, Santa Clara, CA) placement. The severe recurrent commissural MR was successfully managed using an Amplatzer Patent Foramen Ovale Occluder device (St. Jude Medical, Minneapolis, MN) in an off-label fashion.
No takes yet. Share an insight, caveat, or question.
Zughaib et al. (2025) conducted a case report in Severe recurrent commissural mitral regurgitation (n=1). Amplatzer Patent Foramen Ovale Occluder device was evaluated on Reduction in mitral regurgitation and symptom improvement. Off-label use of an 18-mm Amplatzer Patent Foramen Ovale Occluder device successfully reduced severe recurrent commissural mitral regurgitation to mild regurgitation and improved exertional dyspnea.
Synapse has enriched 10 related papers. Consider them for comparative context: